Comparison 8. IV versus oral cyclophosphamide (CPA) plus IV dexamethasone (DEXA).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Treatment response at 6 months	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
1.1 Complete remission	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.2 Partial remission	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.3 Complete or partial remission	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2 Treatment response at 18 months	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
2.1 Sustained remission/steroid‐sensitive relapses	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2.2 CKD	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3 Complete or partial resistance in subgroups	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
3.1 Initial SRNS	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3.2 Late SRNS	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3.3 Minimal change disease	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3.4 FSGS or MesPGN	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4 Adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
4.1 Hypertension	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.2 cataract/glaucoma	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.3 Cushingoid features	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.4 Leucopenia	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.5 Cystitis	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.6 Bacterial infections	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.7 Hypokalaemia	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.8 Steroid encephalopathy	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.9 Hair loss	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]